Lilly announces three acquisitions to build infectious disease portfolio

Key Points:

• Eli Lilly and Company announced agreements to acquire Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc., aiming to expand its infectious disease research and development efforts focused on prevention strategies.
• Curevo’s lead candidate, amezosvatein, is a next-generation shingles vaccine designed to improve tolerability and reduce side effects, potentially increasing vaccination rates and lowering long-term risks such as stroke and dementia.
• LimmaTech Biologics develops vaccines targeting bacterial pathogens with rising antimicrobial resistance, including Staphylococcus aureus and Neisseria gonorrhoeae, with a focus on preventing infections that cause long-term health issues, particularly in women.
• Vaccine Company utilizes In Vivo Nanoparticle technology to develop vaccines against viral pathogens like Epstein-Barr Virus (EBV), which is linked to multiple sclerosis and certain cancers, aiming to prevent both acute infection and long-term complications.
• The acquisitions, subject to regulatory approval, reinforce Lilly’s commitment to disease prevention and are expected to contribute to its financial results following closing, with total potential payments up to $3.83 billion across the three deals.